Sun Pharmas Halol facility concludes USFDA audit with 10 observations

12 May 2022 , 01:33 AM

Sun Pharmaceuticals Industries announced that the US FDA conducted a Good Manufacturing Practices GMP inspection of the companys Halol facility Gujarat India from 26 April to 09 May 2022 At the conclusion of the inspection the US FDA issued a Form-483 with 10 observations The Company is preparing the response to the observations which will be submitted to the US FDA within 15 business days